Par Pharmaceutical, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$2.5M
Doctors Paid
17
Transactions
298
2024 Total
$393.67
Payment Breakdown by Category
Research$2.3M (92.7%)
Consulting$172,151 (6.9%)
Travel$1,234 (0.0%)
Food & Beverage$165.68 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 166 | 92.7% |
| Consulting Fee | $172,151 | 41 | 6.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,103 | 33 | 0.3% |
| Travel and Lodging | $1,234 | 43 | 0.0% |
| Food and Beverage | $165.68 | 15 | 0.0% |
Payments by Type
Research
$2.3M
166 transactions
General
$181,654
132 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Par Pharmaceutical Inc.s Pimecrolimus Cream, and Reference Listed Elidel Pimecrolimus Cream, and Compare Both Active Treatments to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis | $1.3M | 0 | 159 |
| An open label, randomized, two-treatment, two-sequence, four-period, fully-replicated, cross-over, single-dose, bioequivalence study of Testosterone Gel 1.62 Test of Par Pharmaceutical, Inc., USA and AndroGel Testosterone gel 1.62 Reference of AbbVie Inc., USA in healthy, adult, hypogonadal male subjects with no other abnormalities under fasting conditions. | $342,975 | 0 | 1 |
| Project Title An open label, single dose, randomized, 2-way crossover pilot study to evaluate BE between a test product and Adderall XR under fasted and fed condition in healthy volunteers | $324,450 | 0 | 3 |
| An open label, single dose, randomized, 2-way crossover study1 test formulation and 1 reference drug, 3.5 mg sublingual to evaluate BE under fasted condition in healthy volunteers. | $122,694 | 0 | 1 |
| An Open-Label, Randomized, 2 treatment, 2 sequence, 4-Period, fully replicated crossover, Pilot Bioequivalence Study of a test nasal spray and Migranal nasal spray 4 sprays, 0.5 mg each spray in Healthy Adult Subjects Under Fasted Conditions | $119,326 | 0 | 1 |
| A17.0450 | $54,975 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Obstetrics & Gynecology | $19,425 | 1 | $19,425 |
| Cardiovascular Disease | $17,550 | 1 | $17,550 |
| Anesthesiology | $5,691 | 4 | $1,423 |
| Internal Medicine | $3,821 | 3 | $1,274 |
| Pediatrics | $3,600 | 1 | $3,600 |
| Pediatric Nephrology | $1,386 | 1 | $1,386 |
| Clinical Pharmacology | $1,013 | 1 | $1,013 |
| Pulmonary Disease | $867.58 | 1 | $867.58 |
| Rheumatology | $224.34 | 1 | $224.34 |
| Physical Medicine & Rehabilitation | $27.29 | 1 | $27.29 |
| Nurse Anesthetist, Certified Registered | $20.44 | 1 | $20.44 |
| Student in an Organized Health Care Education/Training Program | $19.10 | 1 | $19.10 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Dr. Catherine Bigelow, M.d, M.D | Obstetrics & Gynecology | Minneapolis, MN | $19,425 | $0 |
| Dr. Michael Blaha, M.d., Mph, M.D., MPH | Cardiovascular Disease | Baltimore, MD | $17,550 | $0 |
| Dr. Joseph Pergolizzi, M.d, M.D | Anesthesiology | Naples, FL | $4,264 | $0 |
| Rashed Durgham, Md, MD | Pediatrics | Royal Oak, MI | $3,600 | $0 |
| Dr. Louis Baxter, Md, MD | Internal Medicine | Princeton, NJ | $1,424 | $0 |
| Dr. Alan Kaye, Md, MD | Anesthesiology | New Orleans, LA | $1,386 | $0 |
| Dr. David Goldsmith, M.d, M.D | Pediatric Nephrology | New York, NY | $1,386 | $0 |
| Brian Strom, Md, MD | Internal Medicine | Philadelphia, PA | $1,358 | $0 |
| Jodi Segal, Md, MD | Internal Medicine | Baltimore, MD | $1,039 | $0 |
| Dr. Charles Gorodetzky, M.d., Ph.d, M.D., PH.D | Clinical Pharmacology | Kansas City, MO | $1,013 | $0 |
| Dr. Joseph Hoffman, M.d, M.D | Pulmonary Disease | Park Ridge, NJ | $867.58 | $0 |
| John Cush, M.d, M.D | Rheumatology | Dallas, TX | $224.34 | $0 |
| Mr. Waheed Baksh, Md, Dpt, MD, DPT | Physical Medicine & Rehabilitation | Winchester, VA | $27.29 | $0 |
| Vipul Saparia, Md, MD | Anesthesiology | Memphis, TN | $20.44 | $0 |
| Emily Poppelreiter | Nurse Anesthetist, Certified Registered | Bartlett, TN | $20.44 | $0 |
| Dr. Bo Wu, M.d, M.D | Anesthesiology | Memphis, TN | $20.44 | $0 |
| Christina Kim, M.d, M.D | Student in an Organized Health Care Education/Training Program | Chicago, IL | $19.10 | $0 |
Ad
Top Products
- ZOLPIDEM TARTRATE $122,694
- HYDROCODONE BITARTRATE AND ACETAMINOPHEN $60,402
Associated Products (3)
- ZOLPIDEM TARTRATE $122,694
- HYDROCODONE BITARTRATE AND ACETAMINOPHEN $60,855
- EPINEPHRINESNAP-V $52,125
Payment Categories
- Food & Beverage $165.68
- Consulting $172,151
- Travel & Lodging $1,234
- Research $2.3M
About Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. has made $2.5M in payments to 17 healthcare providers, recorded across 298 transactions in the CMS Open Payments database. In 2024, the company paid $393.67. The top product by payment volume is ZOLPIDEM TARTRATE ($122,694).
Payments were distributed across 12 medical specialties. The top specialty by payment amount is Obstetrics & Gynecology ($19,425 to 1 doctors).
Payment categories include: Food & Beverage ($165.68), Consulting ($172,151), Research ($2.3M), Travel & Lodging ($1,234).
Par Pharmaceutical, Inc. is associated with 3 products in the CMS Open Payments database.